Evaluation of antiviral activity and toxicity of dextran sulfate in feline leukemia virus-infected cats. 1991

L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
Department of Veterinary Pathobiology, Ohio State University, Columbus 43210.

The feline leukemia virus (FeLV) disease model was used to conduct a toxicity and antiretrovirus efficacy trial of dextran sulfate (DS; molecular mass, 7,000 to 8,000 Da). In vitro, FeLV infection of feline lymphoid cells was inhibited by 10 micrograms of DS per ml. DS was administered to cats by continuous intravenous infusion at doses of 600, 120, 24, or 4.8 mg/kg of body weight per day, beginning 24 h before FeLV challenge. Doses of 24 mg/kg/day and more were excessively toxic, causing intestinal lesions and death. Similar changes were observed in unchallenged animals receiving 24 mg/kg/day, indicating that toxicity was DS mediated. The dosage of 4.8 mg/kg/day was subtoxic but did not prevent the induction and persistence of FeLV viremia. The results demonstrate that DS by continuous intravenous infusion is excessively toxic at high doses and ineffective at preventing FeLV infection at a subtoxic dose in the FeLV cat model.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D008221 Lymphoid Tissue Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS. Lymphatic Tissue,Lymphatic Tissues,Lymphoid Tissues,Tissue, Lymphatic,Tissue, Lymphoid,Tissues, Lymphatic,Tissues, Lymphoid
D010948 Viral Plaque Assay Method for measuring viral infectivity and multiplication in CULTURED CELLS. Clear lysed areas or plaques develop as the VIRAL PARTICLES are released from the infected cells during incubation. With some VIRUSES, the cells are killed by a cytopathic effect; with others, the infected cells are not killed but can be detected by their hemadsorptive ability. Sometimes the plaque cells contain VIRAL ANTIGENS which can be measured by IMMUNOFLUORESCENCE. Bacteriophage Plaque Assay,Assay, Bacteriophage Plaque,Assay, Viral Plaque,Assays, Bacteriophage Plaque,Assays, Viral Plaque,Bacteriophage Plaque Assays,Plaque Assay, Bacteriophage,Plaque Assay, Viral,Plaque Assays, Bacteriophage,Plaque Assays, Viral,Viral Plaque Assays
D002415 Cats The domestic cat, Felis catus, of the carnivore family FELIDAE, comprising over 30 different breeds. The domestic cat is descended primarily from the wild cat of Africa and extreme southwestern Asia. Though probably present in towns in Palestine as long ago as 7000 years, actual domestication occurred in Egypt about 4000 years ago. (From Walker's Mammals of the World, 6th ed, p801) Felis catus,Felis domesticus,Domestic Cats,Felis domestica,Felis sylvestris catus,Cat,Cat, Domestic,Cats, Domestic,Domestic Cat
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005256 Leukemia Virus, Feline A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE). Cat Leukemia Virus,FeLV,Feline Lymphoma Virus,Feline Leukemia Virus,Cat Leukemia Viruses,Feline Leukemia Viruses,Feline Lymphoma Viruses,Leukemia Virus, Cat,Leukemia Viruses, Cat,Leukemia Viruses, Feline,Lymphoma Virus, Feline,Lymphoma Viruses, Feline
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D016264 Dextran Sulfate Long-chain polymer of glucose containing 17-20% sulfur. It has been used as an anticoagulant and also has been shown to inhibit the binding of HIV-1 to CD4-POSITIVE T-LYMPHOCYTES. It is commonly used as both an experimental and clinical laboratory reagent and has been investigated for use as an antiviral agent, in the treatment of hypolipidemia, and for the prevention of free radical damage, among other applications. Sodium Dextran Sulfate,Dextran Sulfate Sodium,Dextran Sulfate, Sodium,Sulfate Sodium, Dextran,Sulfate, Dextran,Sulfate, Sodium Dextran

Related Publications

L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
May 1990, Fundamental and applied toxicology : official journal of the Society of Toxicology,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
April 1996, Journal of virology,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
January 2009, Journal of veterinary internal medicine,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
September 1996, Veterinary immunology and immunopathology,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
November 1991, Journal of the American Veterinary Medical Association,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
October 1980, Cancer research,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
October 1998, Veterinary immunology and immunopathology,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
February 1989, Journal of biological response modifiers,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
December 2018, Viruses,
L E Mathes, and K A Hayes, and C L Swenson, and P J Polas, and S E Weisbrode, and G J Kociba
November 1991, Journal of the American Veterinary Medical Association,
Copied contents to your clipboard!